文章：

短程R-CHOP方案继以90Y-伊布莫单抗治疗既往未经治疗的高危老年弥漫大B细胞淋巴瘤患者：7年长期随访结果

Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results

原文发布日期：2016-05-13

DOI: 10.1038/bcj.2016.29

类型: Original Article

开放获取: 是

英文摘要：

An update at 7 years was conceived for our multicenter phase II study in which 55 elderly high-risk untreated diffuse large B-cell lymphoma patients were treated with 90Y-ibritumomab tiuxetan after a short course of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) as long-term follow-up analyses of this combined therapeutic modality are lacking. The overall response rate to the entire regimen was 80%, including 73% (40/55) of complete response (CR) rate and 7% (4/55) of partial response rate. At the time of writing, 24/55 (43.6%) patients experienced a progression disease and 20 of 40 (50%) patients who obtained a CR are still alive in continuous CR. With a median follow-up of 7 years, the disease-free survival was 43.3% and the progression-free survival was 36.1%. The overall survival at 7.9 years was 38.9% (27 deaths mainly because of lymphoma). Two patients developed secondary hematological malignancies, an acute myeloid leukemia and a myelodysplastic syndrome, at 4 and 3 years from radioimmunotherapy, respectively. Our data confirm the feasibility, efficacy and safety of four cycles of R-CHOP followed by radioimmunotherapy consolidation even in the long term: this combination allows dispensing less chemotherapy in a frail group of patients without invalidating response quality and duration.

摘要翻译： 

我们多中心II期研究构思了一项为期7年的更新随访分析，因为目前缺乏关于该联合治疗模式的长期随访数据。该研究纳入了55例高龄高危未经治疗的弥漫性大B细胞淋巴瘤患者，他们在接受短程利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗后，接受了90Y-替伊莫单抗放射免疫治疗。整个治疗方案的总缓解率为80%，其中完全缓解率为73%（40/55），部分缓解率为7%（4/55）。截至撰稿时，24/55（43.6%）患者出现疾病进展，获得完全缓解的40例患者中有20例（50%）仍存活且持续完全缓解。中位随访7年时，无病生存率为43.3%，无进展生存率为36.1%。7.9年总生存率为38.9%（27例死亡，主要死因为淋巴瘤）。2例患者在放射免疫治疗后4年和3年分别发生继发性血液系统恶性肿瘤（急性髓系白血病和骨髓增生异常综合征）。我们的数据证实，即使是长期随访，4周期R-CHOP化疗后联合放射免疫巩固治疗仍具有可行性、有效性和安全性：这种联合方案允许在体弱患者群体中减少化疗剂量，且不影响缓解质量和持续时间。

原文链接：

Short-course R-CHOP followed by 90Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results